Fennec Pharmaceuticals Inc (NASDAQ:FENC – Get Free Report) saw a significant growth in short interest in the month of July. As of July 15th, there was short interest totalling 1,950,000 shares, a growth of 8.3% from the June 30th total of 1,800,000 shares. Approximately 8.6% of the shares of the company are short sold. Based on an average trading volume of 144,300 shares, the short-interest ratio is presently 13.5 days.
Analyst Upgrades and Downgrades
FENC has been the topic of a number of research analyst reports. Wedbush reaffirmed an “outperform” rating and issued a $16.00 target price on shares of Fennec Pharmaceuticals in a report on Tuesday, May 14th. Craig Hallum dropped their target price on shares of Fennec Pharmaceuticals from $20.00 to $17.00 and set a “buy” rating on the stock in a research report on Wednesday, May 15th. Finally, HC Wainwright reduced their price target on shares of Fennec Pharmaceuticals from $18.00 to $15.00 and set a “buy” rating for the company in a report on Wednesday, May 15th.
Get Our Latest Analysis on FENC
Institutional Investors Weigh In On Fennec Pharmaceuticals
Fennec Pharmaceuticals Stock Performance
Shares of NASDAQ FENC traded up $0.02 during trading hours on Thursday, reaching $6.49. The stock had a trading volume of 1,154 shares, compared to its average volume of 123,372. The company has a market cap of $177.37 million, a price-to-earnings ratio of 215.67 and a beta of 0.29. The company has a debt-to-equity ratio of 9.86, a current ratio of 6.93 and a quick ratio of 6.72. The business’s fifty day moving average is $6.52 and its two-hundred day moving average is $8.60. Fennec Pharmaceuticals has a twelve month low of $5.66 and a twelve month high of $11.92.
Fennec Pharmaceuticals (NASDAQ:FENC – Get Free Report) last released its quarterly earnings data on Tuesday, May 14th. The company reported $0.41 EPS for the quarter, missing analysts’ consensus estimates of $0.49 by ($0.08). Fennec Pharmaceuticals had a negative return on equity of 39.41% and a net margin of 6.33%. The business had revenue of $25.38 million for the quarter, compared to the consensus estimate of $10.46 million. During the same period in the previous year, the business posted ($0.23) earnings per share. As a group, research analysts expect that Fennec Pharmaceuticals will post 0.36 EPS for the current year.
Fennec Pharmaceuticals Company Profile
Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children.
Read More
- Five stocks we like better than Fennec Pharmaceuticals
- The How and Why of Investing in Gold Stocks
- Mastercard Stock’s Q2 Financial Results Outshine Competitors
- How to Use the MarketBeat Excel Dividend Calculator
- Tobacco Giant’s Shares Fall on EPS Miss, Lackluster Pouch Gains
- The Significance of Brokerage Rankings in Stock Selection
- Analysts Expect At Least 60% Upside In This Fintech
Receive News & Ratings for Fennec Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fennec Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.